一体化18F-FDG PET/MR能否替代恶性黑色素瘤的前哨淋巴结切除
该回顾性研究纳入52例恶性黑色素瘤患者,对比18F-FDG PET/CT、PET/MR及PET/MR联合DWI检测前哨淋巴结转移的效能,以SPECT/CT引导下前哨淋巴结活检病理为参考标准。PET/CT灵敏度17.7%、特异度95.6%,PET/MR灵敏度23.5%、特异度96.9%;DWI未提高灵敏度。作者结论为PET/MR不能可靠区分N阳性与N阴性患者,前哨淋巴结活检不能被替代。
要点
- PET/CT灵敏度17.7%、特异度95.6%,PET/MR灵敏度23.5%、特异度96.9%。
- DWI未增加真阳性发现,反而增加2个假阳性。
- 作者结论:PET/MR不能可靠区分N阳性与N阴性患者,前哨淋巴结活检不能被替代。
核心结论
- 一体化18F-FDG PET/MR不能可靠区分N阳性与N阴性恶性黑色素瘤患者。
- 附加DWI未提高18F-FDG PET/MR的灵敏度。
- 前哨淋巴结活检不能被18F-FDG PET/MR或18F-FDG PET/CT替代。
研究设计与样本
- 回顾性研究纳入52例恶性黑色素瘤患者(女性30例,男性22例,平均年龄50.5±16.0岁,平均肿瘤厚度2.28±1.97 mm)。
- 患者接受18F-FDG PET/CT及后续PET/MR与DWI用于远处转移分期。
- 混合成像后行淋巴显像包括SPECT/CT以识别前哨淋巴结,随后行前哨淋巴结活检。
- SPECT/CT可见64个淋巴结引流区的87枚前哨淋巴结,组织病理学检出17枚淋巴结转移。
- 由两名独立阅片者分别评估PET/CT、PET/MR和PET/MR联合DWI,分歧经共识阅片解决。
主要发现
- 以SPECT/CT引导下前哨淋巴结活检后组织病理学为参考标准,PET/CT真阳性3例、真阴性65例、假阳性3例、假阴性14例。
- PET/MR真阳性4例、真阴性63例、假阳性2例、假阴性13例。
- PET/CT灵敏度17.7%、特异度95.6%、阳性预测值50.0%、阴性预测值82.3%。
- PET/MR灵敏度23.5%、特异度96.9%、阳性预测值66.7%、阴性预测值82.3%。
- DWI可分析56个前哨淋巴结引流区,附加DWI分析导致2个额外假阳性发现,真阳性发现数未能增加。
关键数值与推荐
- PET/CT灵敏度17.7%、特异度95.6%、阳性预测值50.0%、阴性预测值82.3%。
- PET/MR灵敏度23.5%、特异度96.9%、阳性预测值66.7%、阴性预测值82.3%。
临床怎么用
- 作者结论认为前哨淋巴结活检不能被18F-FDG PET/MR或18F-FDG PET/CT替代。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the sensitivity and specificity of 18F-fluordesoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), 18F-FDG PET/magnetic resonance (18F-FDG PET/MR) and 18F-FDG PET/MR including diffusion weighted imaging (DWI) in the detection of sentinel lymph node metastases in patients suffering from malignant melanoma. MATERIAL & METHODS: Fifty-two patients with malignant melanoma (female: n = 30, male: n = 22, mean age 50.5 ± 16.0 years, mean tumor thickness 2.28 ± 1.97 mm) who underwent 18F-FDG PET/CT and subsequent PET/MR & DWI for distant metastasis staging were included in this retrospective study. After hybrid imaging, lymphoscintigraphy including single photon emission computed tomography/CT (SPECT/CT) was performed to identify the sentinel lymph node prior to sentinel lymph node biopsy (SLNB). In a total of 87 sentinel lymph nodes in 64 lymph node basins visible on SPECT/CT, 17 lymph node metastases were detected by histopathology. In separate sessions PET/CT, PET/MR, and PET/MR & DWI were assessed for sentinel lymph node metastases by two independent readers. Discrepant results were resolved in a consensus reading. Sensitivities, specificities, positive predictive values and negative predictive values were calculated with histopathology following SPECT/CT guided SLNB as a reference standard. RESULTS: Compared with histopathology, lymph nodes were true positive in three cases, true negative in 65 cases, false positive in three cases and false negative in 14 cases in PET/CT. PET/MR was true positive in four cases, true negative in 63 cases, false positive in two cases and false negative in 13 cases. Hence, we observed a sensitivity, specificity, positive predictive value and negative predictive value of 17.7, 95.6, 50.0 and 82.3% for PET/CT and 23.5, 96.9, 66.7 and 82.3% for PET/MR. In DWI, 56 sentinel lymph node basins could be analyzed. Here, the additional analysis of DWI led to two additional false positive findings, while the number of true positive findings could not be increased. CONCLUSION: In conclusion, integrated 18F-FDG PET/MR does not reliably differentiate N-positive from N-negative melanoma patients. Additional DWI does not increase the sensitivity of 18F-FDG PET/MR. Hence, sentinel lymph node biopsy cannot be replaced by 18F-FDG-PE/MR or 18F-FDG-PET/CT.
引用
- Schaarschmidt BM, Grueneisen J, Stebner V, et al. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma? Eur J Nucl Med Mol Imaging. 2018. PMID: 29876618. doi:10.1007/s00259-018-4061-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。